CN Patent

CN103402969A — 3-酰基-巨大戟二萜醇ii

Assigned to Leo Pharma AS · Expires 2013-11-20 · 12y expired

What this patent protects

本发明涉及通式I的化合物，其中R是被R3的取代的芳基；或R是(C 3 -C 13 )-环烷基、(C 3 -C 13 )-环烯基或(C 7 -C 13 )-环炔基，其任选地被R4所取代；及其可药用盐、水合物或溶剂化物，其用于单独地或与一种或多种其它的药用活性化合物组合用于疗法中，用于预防、治疗或改善对刺激嗜中性粒细胞突发性氧化作用有积极响应的、对刺激角质形成细胞IL-8释放有积极响应的或对诱导坏死有积极响应的疾病或病症。

USPTO Abstract

本发明涉及通式I的化合物，其中R是被R3的取代的芳基；或R是(C 3 -C 13 )-环烷基、(C 3 -C 13 )-环烯基或(C 7 -C 13 )-环炔基，其任选地被R4所取代；及其可药用盐、水合物或溶剂化物，其用于单独地或与一种或多种其它的药用活性化合物组合用于疗法中，用于预防、治疗或改善对刺激嗜中性粒细胞突发性氧化作用有积极响应的、对刺激角质形成细胞IL-8释放有积极响应的或对诱导坏死有积极响应的疾病或病症。

Drugs covered by this patent

Patent Metadata

Patent number
CN103402969A
Jurisdiction
CN
Classification
—
Expires
2013-11-20
Drug substance claim
No
Drug product claim
No
Assignee
Leo Pharma AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.